BridgeBio contributes rare disease assets to $300M-backed GondolaBio venture

[cafead]

via With $300 million in financing from a syndicate of investors, the company is forming a new joint venture called GondolaBio to which it has transferred certain early-stage clinical and preclinical programmes focused on erythropoietic protoporphyria, alpha-1 antitrypsin deficiency and tuberous sclerosis complex.

article source